Nuvalent Past Earnings Performance
Past criteria checks 0/6
Nuvalent's earnings have been declining at an average annual rate of -49.6%, while the Biotechs industry saw earnings growing at 19.3% annually.
Key information
-49.6%
Earnings growth rate
32.4%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | n/a |
| Return on equity | -20.0% |
| Net Margin | n/a |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
No updates
Recent updates
Nuvalent: Steps Toward That Favorable Entry Point
Dec 07We're Hopeful That Nuvalent (NASDAQ:NUVL) Will Use Its Cash Wisely
Nov 18
Nuvalent: Promising Data Keeps Validating Pipeline And Platform
Sep 23Nuvalent: Likely Approvals Coming Up Do Not Justify This Valuation
Sep 17Nuvalent (NASDAQ:NUVL) Is In A Strong Position To Grow Its Business
Aug 05Nuvalent: Making Precise Progress In Its Oncology Pipeline
Jun 24Nuvalent: NVL-655 Could Bring Blockbuster Potential
Jun 14Here's Why We're Not Too Worried About Nuvalent's (NASDAQ:NUVL) Cash Burn Situation
Apr 22Nuvalent: Pivotal NSCLC Programs Progressing With Additional Data In 2024
Feb 26Is Nuvalent, Inc. (NASDAQ:NUVL) Trading At A 36% Discount?
Jan 07Nuvalent GAAP EPS of -$0.38 beats by $0.03
Aug 10Revenue & Expenses Breakdown
How Nuvalent makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 0 | -224 | 57 | 184 |
| 30 Jun 24 | 0 | -174 | 50 | 153 |
| 31 Mar 24 | 0 | -146 | 42 | 130 |
| 31 Dec 23 | 0 | -126 | 36 | 113 |
| 30 Sep 23 | 0 | -114 | 32 | 101 |
| 30 Jun 23 | 0 | -100 | 28 | 86 |
| 31 Mar 23 | 0 | -89 | 25 | 73 |
| 31 Dec 22 | 0 | -82 | 22 | 64 |
| 30 Sep 22 | 0 | -73 | 20 | 54 |
| 30 Jun 22 | 0 | -66 | 18 | 49 |
| 31 Mar 22 | 0 | -57 | 15 | 43 |
| 31 Dec 21 | 0 | -46 | 10 | 36 |
| 30 Sep 21 | 0 | -36 | 7 | 27 |
| 30 Jun 21 | 0 | -28 | 4 | 22 |
| 31 Mar 21 | 0 | -27 | 2 | 18 |
| 31 Dec 20 | 0 | -15 | 2 | 15 |
Quality Earnings: NUVL is currently unprofitable.
Growing Profit Margin: NUVL is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: NUVL is unprofitable, and losses have increased over the past 5 years at a rate of 49.6% per year.
Accelerating Growth: Unable to compare NUVL's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: NUVL is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).
Return on Equity
High ROE: NUVL has a negative Return on Equity (-20.01%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/26 16:59 |
| End of Day Share Price | 2024/12/26 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Nuvalent, Inc. is covered by 16 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Colleen Kusy | Baird |
| Peter Lawson | Barclays |
| Evan Seigerman | BMO Capital Markets Equity Research |